Treatment Options in Chronic Lymphocytic Leukemia: A Global Perspective
Episodes
Specialty:
All
All AI for Oncology Biosimilars Brain Cancer Breast Cancer CAR T-Cell Therapy Disparities in Cancer Care Gastrointestinal Cancer Genitourinary Cancers Global Oncology Graft-vs-Host Disease Gynecologic Oncology Head & Neck Cancers Hematologic Oncology Immuno-Oncology Lung Cancer Melanoma & Skin Cancer Oncology Business Management Pediatric Oncology Precision Medicine in Oncology® Sarcomas Supportive Care
EP. 1: Treatment Considerations in Newly Diagnosed CLL By Stephan Stilgenbauer, MD, Ulm University, Paolo Ghia, MD, Phd, Universita Vita-Salute San Raffaele, Jennifer Brown, MD, PhD, Dana-Farber Cancer Institute Drs Stilgenbauer and Ghia provide insight on initial treatment considerations for patients with newly diagnosed chronic lymphocytic leukemia.
EP. 2: Guidelines for Chronic Lymphocytic Leukemia By Stephan Stilgenbauer, MD, Ulm University, Paolo Ghia, MD, Phd, Universita Vita-Salute San Raffaele, Jennifer Brown, MD, PhD, Dana-Farber Cancer Institute Dr Brown and Dr Ghia discuss the European Society for Medical Oncology [ESMO] and International Workshop on Chronic Lymphocytic Leukemia [iwCLL] recommended guidelines in assessing and treating chronic lymphocytic leukemia.
EP. 3: Frontline Treatment Options in Chronic Lymphocytic Leukemia By Stephan Stilgenbauer, MD, Ulm University, Paolo Ghia, MD, Phd, Universita Vita-Salute San Raffaele, Jennifer Brown, MD, PhD, Dana-Farber Cancer Institute The experts comment on first-line treatment options in patients with chronic lymphocytic leukemia.
EP. 4: BTK Inhibitors in Treatment of Chronic Lymphocytic Leukemia By Stephan Stilgenbauer, MD, Ulm University, Paolo Ghia, MD, Phd, Universita Vita-Salute San Raffaele, Jennifer Brown, MD, PhD, Dana-Farber Cancer Institute Dr Ghia provides an in-depth conversation on the use of Bruton tyrosine kinase inhibitors in treating chronic lymphocytic leukemia.
EP. 5: Clinical Trials With BTK Inhibitors in Chronic Lymphocytic Leukemia By Stephan Stilgenbauer, MD, Ulm University, Paolo Ghia, MD, Phd, Universita Vita-Salute San Raffaele, Jennifer Brown, MD, PhD, Dana-Farber Cancer Institute Dr Brown provides a brief overview of data available that support the use of Bruton’s tyrosine kinase inhibitors in treating chronic lymphocytic leukemia; Dr Stilgenbauer comments on mitigating and managing adverse effects in the treatment of chronic lymphocytic leukemia.
EP. 6: Acalabrutinib in the Treatment of Chronic Lymphocytic Leukemia By Stephan Stilgenbauer, MD, Ulm University, Paolo Ghia, MD, Phd, Universita Vita-Salute San Raffaele, Jennifer Brown, MD, PhD, Dana-Farber Cancer Institute Experts provide insight on the use of acalabrutinib in treating chronic lymphocytic leukemia.
EP. 7: A Look at the ELEVATE-TN and ASCEND Trials By Stephan Stilgenbauer, MD, Ulm University, Paolo Ghia, MD, Phd, Universita Vita-Salute San Raffaele, Jennifer Brown, MD, PhD, Dana-Farber Cancer Institute Dr Stilgenbauer explains the ELEVATE-TN and ASCEND clinical trials; Dr Brown highlights the adverse effects seen with acalabrutinib.
EP. 8: A Look at the ECOG 1912 and iLLUMINATE Trials By Stephan Stilgenbauer, MD, Ulm University, Paolo Ghia, MD, Phd, Universita Vita-Salute San Raffaele, Jennifer Brown, MD, PhD, Dana-Farber Cancer Institute Experts Dr Stilgenbauer and Dr Ghia highlight and comment on the ECOG 1912 and iLLUMINATE trials.
EP. 9: Role of Venetoclax in Chronic Lymphocytic Leukemia By Stephan Stilgenbauer, MD, Ulm University, Paolo Ghia, MD, Phd, Universita Vita-Salute San Raffaele, Jennifer Brown, MD, PhD, Dana-Farber Cancer Institute Experts comment on the use of venetoclax-based therapy in treating chronic lymphocytic leukemia.
EP. 10: Chronic Lymphocytic Leukemia Treatment Considerations By Stephan Stilgenbauer, MD, Ulm University, Paolo Ghia, MD, Phd, Universita Vita-Salute San Raffaele, Jennifer Brown, MD, PhD, Dana-Farber Cancer Institute Dr Brown and Dr Stilgenbauer provide advice for community-based oncologists treating chronic lymphocytic leukemia.
EP. 11: Treatment Options in Relapsed/Refractory Chronic Lymphocytic Leukemia By Stephan Stilgenbauer, MD, Ulm University, Paolo Ghia, MD, Phd, Universita Vita-Salute San Raffaele, Jennifer Brown, MD, PhD, Dana-Farber Cancer Institute Experts discuss second-line treatment options in relapsed/refractory chronic lymphocytic leukemia, including a discussion on the MURANO trial.
EP. 12: Treatment Sequencing in Chronic Lymphocytic Leukemia By Stephan Stilgenbauer, MD, Ulm University, Paolo Ghia, MD, Phd, Universita Vita-Salute San Raffaele, Jennifer Brown, MD, PhD, Dana-Farber Cancer Institute Experts provide an in-depth look at their approach in sequencing treatment in chronic lymphocytic leukemia.
EP. 13: The Future of Chronic Lymphocytic Leukemia Treatment By Stephan Stilgenbauer, MD, Ulm University, Paolo Ghia, MD, Phd, Universita Vita-Salute San Raffaele, Jennifer Brown, MD, PhD, Dana-Farber Cancer Institute Dr Ghia discusses emerging treatment strategies, including some promising clinical trials in chronic lymphocytic leukemia.
EP. 14: Novel Treatment Combinations in Chronic Lymphocytic Leukemia By Stephan Stilgenbauer, MD, Ulm University, Paolo Ghia, MD, Phd, Universita Vita-Salute San Raffaele, Jennifer Brown, MD, PhD, Dana-Farber Cancer Institute Dr Brown and Dr Stilgenbauer provide their input on novel treatment options emerging for chronic lymphocytic leukemia.
